Showing 4421-4430 of 6036 results for "".
- Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase 1/2 Clinical Trial of ATSN-101 in Patients with LCA1https://modernod.com/news/atsena-therapeutics-announces-positive-6-month-data-from-ongoing-phase-12-clinical-trial-of-atsn-101-in-patients-with-lca1/2481563/Atsena Therapeutics announced positive 6-month safety and efficacy data from the ongoing phase 1/2 clinical trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data were presented by Chris
- Zeiss Receives FDA Approval of the CT Lucia 621P Monofocal IOLhttps://modernod.com/news/zeiss-receives-fda-approval-of-the-ct-lucia-621p-monofocal-iol/2481561/Zeiss announced that the FDA has approved the CT Lucia 621P monofocal IOL, an aspheric, monofocal, single-piece C-loop IOL. The IOL features the patented Zeiss Optic (ZO) Asphericity Concept, which is designed to compensate for a wide range of spherical aberrations and at
- Johnson & Johnson Vision Showcases 30 New Sets of Scientific Data on Myopia, Refractive Technologies, IOLs and More at ARVOhttps://modernod.com/news/johnson-johnson-vision-showcases-30-new-sets-of-scientific-data-on-myopia-refractive-technologies-iols-and-more-at-arvo/2481554/Johnson & Johnson Vision announced that it is presenting 30 sets of research spanning the spectrum of eye health including myopia, refractive technology, sphere, intraocular lenses, astigmatism, consumer eye health, and vision science at the Association for Research in Vision and Ophthalmolog
- Apellis Presents Phase 3 Functional Analyses of Syfovre for Geographic Atrophyhttps://modernod.com/news/apellis-presents-phase-3-functional-analyses-of-syfovre-for-geographic-atrophy/2481553/Apellis Pharmaceuticals announced post hoc analyses from the 24-month, phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analyses were reported during oral presenta
- Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at ASCRS and ARVOhttps://modernod.com/news/azura-ophthalmics-to-present-new-data-on-azr-md-001-in-meibomian-gland-dysfunction-at-ascrs-and-arvo/2481544/Azura Ophthalmics announced multiple presentations featuring positive efficacy and safety data from a phase 2b study of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD). Data will be featured at the upcoming Annual Meetings for the Association for Research
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-3-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481543/Visus Therapeutics reported positive topline results from its phase 3 pivotal BRIO-I trial. BRIO-I met the prespecified primary study endpoints agreed upon with the FDA and EMA/MHRA, demonstrating contribution of elements for the once-daily, fixed-dose combination, Brimochol PF, over both ac
- Iridex Announces US Launch of Next Generation PASCAL Laser with MicroPulsehttps://modernod.com/news/iridex-launches-next-gen-pascal-laser-with-micropulse-in-us/2481542/Iridex announced the full market launch of the next generation Iridex PASCAL platform. First offered in limited release in late 2022, the PASCAL is designed to provide an advanced technology package combining fast and precise pattern scanning capabilities, Endpoint Management Techn
- Nidek Launches the NT-1/1e Non Contact Tonometerhttps://modernod.com/news/nidek-launches-the-nt-11e-non-contact-tonometer/2481535/Nidek has announced the launch of the NT-1/1e non contact tonometer models. As an addition to same series that includes the NT-1p, the NT-1/1e non-contact tonometers were developed without the pachymetry function to address market demand. The NT-1p/1 perform fully automated measur
- Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of Gene Therapy OCU400, for the Treatment of RP and LCAhttps://modernod.com/news/ocugen-announces-positive-preliminary-safety-and-efficacy-results-from-the-phase-12-trial-of-gene-therapy-ocu400-for-the-treatment-of-rp-and-lca/2481534/Ocugen announced positive preliminary data among retinitis pigmentosa (RP) participants treated in the first two cohorts of the phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations and Leber Congenital Amaurosis (LCA) wit
- Haag-Streit Launches New EyeSuite Softwarehttps://modernod.com/news/haag-streit-launches-new-eyesuite-software/2481532/Haag-Streit has announced the launch of EyeSuite software version i9.13, which offers new features for the Eyestar 900’s Anterior Chamber Suite and market-first functionality for the Lenstar Myopia. In addition, it’s existing portfolio of I